*1.Did this session meet the stated objectives below?(Required.)

Yes

No

Summarize the evidence for emerging biologic and small molecule therapies in IBD, including TL1A antagonists, IL-23 inhibitors, and anti-fibrotic agents, and identify appropriate patient populations for each.

Yes

No

Review current surgical and endoscopic management approaches to ulcerative colitis, integrating multidisciplinary perspectives.

Yes

No

Evaluate the evidence for and against dual biologic therapy in IBD, including patient selection criteria, safety considerations, and monitoring strategies.

Yes

No

Discuss evolving treatment targets and the implications of a treat-to-target strategy for long-term disease management in IBD.

Yes

No

*2.Did you perceive any degree of commercial or other inappropriate bias during this session?(Required.)

No

Yes

*3.Please provide a score for the following:(Required.)

Poor

Fair

Good

Very Good

Excellent

Usefulness/Practicality of the presentation

Poor

Fair

Good

Very Good

Excellent

Scientific content of this presentation

Poor

Fair

Good

Very Good

Excellent

Effectiveness of the speaker(s)

Poor

Fair

Good

Very Good

Excellent

Presentation format

Poor

Fair

Good

Very Good

Excellent

Adequate time for questions/discussion

Poor

Fair

Good

Very Good

Excellent

4.If you have further feedback or suggestions about this session or the overall summit, please add it below.